Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

Journal of Clinical Oncology

Volumn 18, Issue 16, 2000, Pages 2938-2947

  de Gramont, A ^a   Figer, A ^a   Seymour, M ^a   Homerin, M ^a   Hmissi, A ^a   Cassidy, J ^a   Boni, C ^a   Cortes Funes, H ^a   Cervantes, A ^a   Freyer, G ^a   Papamichael, D ^a   Le Bail, N ^a   Louvet, C ^a   Hendler, D ^a   De Braud, F ^a   Wilson, C ^a   Morvan, F ^a   Bonetti, A ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033874892     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.16.2938     Document Type: Article

References (43)

1. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer: The Nordic Gastrointestinal Tumor Adjuvant Therapy Group
2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
3. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
4. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
5. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers
6. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
7. Oxaliplatin activity against metastatic colorectal cancer: A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
8. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
9. A phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
10. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
11. Bimonthly high-dose leucovorin, 5-fluorouracil 48-hour infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same LV-5FU regimen
12. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases: A randomized multiinstitutional trial
13. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
14. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials
15. One sample multiple testing procedure for phase II clinical trials
16. Interim analysis in randomized clinical trials: Ramifications and guidelines for practitioners
17. Statistical aspects of the analysis of data from retrospective studies of disease
18. Nonparametric estimation from incomplete observations
19. Regression models and life-tables
20. Randomized trial assessing the addition of interferon-2-alpha to fluorouracil and leucovorin in advanced colorectal cancer
21. A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer
22. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: Final results of a randomized European Organization for Research and Treatment of Cancer study
23. Folinic acid + 5-fluorouracil (5-FU) versus equidose of 5-FU in advanced colorectal cancer: Phase III study of GISCAD (Italian group for the study of digestive tract cancer)
24. Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal cancer
25. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: A randomized phase III study
26. Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: A randomized study
27. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
28. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy
29. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
30. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
31. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
32. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
33. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
34. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
35. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer
36. Randomized comparative study of Orzel (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FY) plus LV in patients with metastatic colorectal cancer
37. Multicenter randomized trial of 5-fluorouracil (5FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in patients with advanced colorectal cancer
38. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: A multicentre randomised trial
39. Weekly irinotecan, leucovorin and fluorouracil is superior to dailyx5 LV/FU in patients with prviously untreated metastatic colorectal cancer
40. A simplified bimonthly regimen with leucovorin and 5-fluorouracil for metastatic colorectal cancer
41. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)